Moderna, Inc. (MRNA) Net Profit Margin: -143.55%
Is Moderna, Inc.’s net profit margin high or low?
Moderna, Inc.'s net profit margin of -143.55% is 182% below its 5-year average of -50.87%, near the low end of its 5-year range (-145.16%–68.80%).
The net profit margin for Moderna, Inc. (MRNA) is -143.55% as of Wednesday, June 10, 2026. It is below its 12-month average by 11.94% (-128.24%).
MRNA Net Profit Margin Chart
MRNA Average Net Profit Margin Chart
MRNA Current vs Average Net Profit Margin Chart
MRNA Net Profit Margin Metrics
NET PROFIT MARGIN
-143.55%
NET PROFIT MARGIN AVG TTM
-128.24%
NET PROFIT MARGIN AVG 3Y
-70.25%
NET PROFIT MARGIN AVG 5Y
-50.87%
NET PROFIT MARGIN AVG 10Y
-176.76%
NET PROFIT MARGIN AVG 15Y
-176.76%
NET PROFIT MARGIN AVG 20Y
-176.76%
CURRENT VS TTM AVG
-11.94%
CURRENT VS 3Y AVG
-104.33%
CURRENT VS 5Y AVG
-182.20%
CURRENT VS 10Y AVG
+18.79%
CURRENT VS 15Y AVG
+18.79%
CURRENT VS 20Y AVG
+18.79%
MRNA Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $18.40B | -143.55% | -128.24% | -70.25% | -50.87% |
| Hologic, Inc. (HOLX) | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| BioNTech SE (BNTX) | $21.81B | -44.73% | -31.89% | 3.77% | 12.08% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 21.40% | 21.94% | 21.74% | 21.20% |
| Waters Corporation (WAT) | $23.83B | 11.91% | 20.93% | 21.85% | 22.39% |
| Align Technology, Inc. (ALGN) | $12.56B | 10.50% | 10.36% | 10.48% | 22.21% |
| Baxter International Inc. (BAX) | $10.49B | -9.70% | -7.30% | -3.29% | 1.14% |
| Veeva Systems Inc. (VEEV) | $26.73B | 28.37% | 27.22% | 24.83% | 24.72% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -4.59% | -1.67% | 5.09% | 7.31% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 6.52% | -21.22% | -48.94% | 16.61% |
Margin Comparison
Operating Margin
-153.3%
Net Profit Margin
-143.6%
Moderna, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. Net Profit Margin FAQ
- What is the net profit margin for Moderna, Inc. (MRNA)?
- The net profit margin for MRNA stock is -143.55%.
- Is Moderna, Inc.'s net profit margin high or low?
- Moderna, Inc.'s net profit margin of -143.55% is 182% below its 5-year average of -50.87%, near the low end of its 5-year range (-145.16%–68.80%).
- What is the TTM average net profit margin for Moderna, Inc. (MRNA)?
- The TTM average net profit margin for MRNA stock is -128.24%.
- What is the 3Y average net profit margin for Moderna, Inc. (MRNA)?
- The 3Y average net profit margin for MRNA stock is -70.25%.
- What is the 5Y average net profit margin for Moderna, Inc. (MRNA)?
- The 5Y average net profit margin for MRNA stock is -50.87%.
- What is the 10Y average net profit margin for Moderna, Inc. (MRNA)?
- The 10Y average net profit margin for MRNA stock is -176.76%.
- What is the 15Y average net profit margin for Moderna, Inc. (MRNA)?
- The 15Y average net profit margin for MRNA stock is -176.76%.
- What is the 20Y average net profit margin for Moderna, Inc. (MRNA)?
- The 20Y average net profit margin for MRNA stock is -176.76%.
Moderna, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -145.16% |
| 2024-12-31 | -111.32% |
| 2023-12-31 | -68.84% |
| 2022-12-31 | 44.30% |
| 2021-12-31 | 68.80% |
| 2020-12-31 | -92.99% |
| 2019-12-31 | -853.73% |
| 2018-12-31 | -284.84% |
| 2017-12-31 | -124.34% |
| 2016-12-31 | -199.46% |
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel